Page 13 - Trial Network News Today

PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases

Search jobs 24-Dec-2020 INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancets EClinicalMedicine PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from...

Hummingbird, Tempus collaborate to harness AI-driven precision medicine One percent of all solid tumors harbor NRG1 fusions, a rare genetic mutation that drives malignancies. Singapore biotech company Hummingbird Bioscience has announced a collaboration with technology company Tempus to harness AI and big data in support of a biomarker-driven clinical trial for Hummingbird’s anti-HER3 antibody, HMBD-001, including those that harbor neuregulin 1 (NRG1) fusions. NRG1 fusions are a rare genetic ...

Published: Dec 15, 2020   PLYMOUTH MEETING, Pa., Dec. 15, 2020 /PRNewswire/ -- Inovio (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the company and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the Defense Advanced Research Projects Agency (DARPA) (D...

Share this article Share this article SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbirds lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1...

About the INO-4800 "INNOVATE" Phase 2/3 Clinical Trial The lead Principal Investigator for INNOVATE is Dr. Pablo Tebas, Professor of Medicine at the Hospital of the University of Pennsylvania. The Phase 2 segment of the clinical trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization (in a planned total of 400 subjects) to receive either INO-4800 or placebo, to confirm the more appropriate dosing l...